US20100234291A2 - Preparation and use of low-bleeding anticoagulant fusion protein - Google Patents
Preparation and use of low-bleeding anticoagulant fusion protein Download PDFInfo
- Publication number
- US20100234291A2 US20100234291A2 US12/519,309 US51930907A US2010234291A2 US 20100234291 A2 US20100234291 A2 US 20100234291A2 US 51930907 A US51930907 A US 51930907A US 2010234291 A2 US2010234291 A2 US 2010234291A2
- Authority
- US
- United States
- Prior art keywords
- recognizable
- coagulation factor
- cleavable
- oligopeptide
- thrombin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6443—Coagulation factor XIa (3.4.21.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21027—Coagulation factor XIa (3.4.21.27)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention belongs to the area of biotechnology, and relates to structure and preparation of a kind of anticoagulant substances with low hemorrhage and their application in prevention and treatment of thrombosis and thrombosis-related diseases.
- this invention is related to a new substance obtained by linking an anticoagulant substance and an amino acid sequence being recognizable and cleavable by several blood coagulation factors, including thrombin, blood coagulation factor Xa (FXa) and XIa (FXIa) etc., and the preparation and pharmaceutical use of the same.
- Cardio-cerebrovascular diseases are number one killer threatening human health and life, and thrombosis is an important cause of many cardio-cerebrovascular diseases. Therefore, anticoagulants are important medicines used to prevent thrombosis.
- heparin is an anticoagulant extensively used in clinical treatment. But one of its important shortcomings is to initiate thrombocytopenia. The newly developed Low-Molecular-Weight (LMW) heparin might decrease above risks, but can not thoroughly overcome its shortcomings.
- LMW Low-Molecular-Weight
- the anticoagulant function should be conditionally and specifically activated. That is, this kind of material normally has no anticoagulant activity, and only when the coagulation system is activated, and thrombus is possible to form or the thrombus formed, then this kind of anticoagulant locally display their anticoagulant activities.
- the local anticoagulant activity around the developing or developed thrombus forms a microenvironment to prevent thrombosis or the continued growing of the thrombus, even to dissolve the formed minute thrombus so as to attain the prophylactic/therapeutic purposes. Therefore, this invention would overcome the risk of systemic hemorrhage which often happens with administration of anticoagulant agents, such as heparin, hirudin etc.
- hirudin is a single chain polypeptide consisting of 65-66 amino acid residues, whose amino terminus can bind with the catalytic active site of thrombin, and possesses anticoagulant activity, and the binding of its C-terminus with the recognition site of thrombin substrate shows a very strong specific affinity to thrombin.
- This study designed a measure to block the amino-terminus of hirudin so as to diminish hirudin's anticoagulant activity temporarily.
- hirudin was modified in this study. Hirudin first was linked by its amino-terminal with an oligopeptide recognizable and cleavable by thrombin, which is named as TH, or with an oligopeptide recognizable and cleavable by blood coagulation factor Xa, which is named as FH, so that once the coagulation system was activated, the anticoagulant activity of hirudin derivatives could be released and play the anticoagulant and antithrombotic roles, while the hemorrhagic side-effect would be also decreased. The results indicated that the modified hirudin was functional, but the effectiveness was not still high enough.
- hirudin might be modified by linking with an oligopeptide which can be recognized and cleaved by several blood coagulation factors or other factors. We hoped that the effectiveness could be enhanced by the above-mentioned modification to the extent of applicability to clinical practice. At present, however, on the basis of the related references, we can not infer if these oligopeptides can be recognized and cleaved by the corresponding blood coagulation factors in high efficiency.
- hirudin was linked at its amino-terminal with the oligopeptide being recognizable and cleavable by both thrombin and coagulation factor Xa, this hirudin derivative being named as GH; (2) hirudin was linked at its amino-terminal with the oligopeptide being recognizable and cleavable by both coagulation factors XIa and Xa, this hirudin derivative being named as EH.
- This invention is aimed at providing a kind of substance which has no anticoagulant activity itself and can release its anticoagulation activity around the site of thrombosis when thrombosis tends to occur or is occurring for prevention and/or treatment of thrombosis.
- the anticoagulation activity of the anticoagulation substance could be blocked by linking the anticoagulation substance with a sequence recognizable by both coagulation factor XIa and Xa, or a sequence recognizable by both thrombin and coagulation factor Xa, and the new anticoagulation substance is cleavable at certain conditions.
- the derivatized anticoagulation substances possess the following characteristics: after blocked by a sequence recognizable by the above-mentioned two blood coagulation factors, the anticoagulation substance, such as hirudin, has no anticoagulation activity both in vitro and in non-thrombotic site of blood system, thus avoiding or decreasing the side-effects of systemic hemorrhage caused by anticoagulation substances, such as hirudin; the derivatized anticoagulation substances can locally release free anticoagulant substances under the action of blood coagulation factors specifically present in the site of thrombosis only when the thrombosis occurs, thus displays a prophylactic and/or therapeutic effects against thrombosis, and therefore significantly decreases the side-effect of systemic hemorrhage.
- the new anticoagulation substance such as the amino-terminus of hirudin, blocked with a two coagulation factors-recognized sequence, can be cleaved by two coagulation factors together, the effectiveness of which is greatly superior to that of the block of anticoagulation substance by a one coagulation factor-recognized sequence.
- this invention is related to an anticoagulation substance which comprises an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together.
- This invention is related to a method for preparation of an anticoagulation substance comprising an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together, which comprises ligating a gene encoding anticoagulation protein with an base sequence corresponding to the sequence recognizable and cleavable by coagulation factors XIa and Xa together, or to the sequence recognizable and cleavable by thrombin and coagulation factor Xa together, then inserting the recombinant gene into a suitable expression vector, such as pBV220, pPIC9, and pPIC9K etc, and expressing the recombinant vector containing the gene of interest in appropriate host cells, such as Escherichia coli , yeast or animal cell systems, so as to obtain the new anticoagulation substance.
- a suitable expression vector such as pBV220
- this invention is related to a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned new anticoagulation substance and a pharmaceutically acceptable carrier or excipient.
- anticoagulant substance indicates a substance against blood coagulation, such as hirudin, antithrombin III, snake venom etc. or their mutants; or the other substances with anticoagulation activity, preferably hirudin or its mutants.
- the terms “linked peptide recognizable by coagulation factors XIa and Xa together or linked peptide recognizable by thrombin and coagulation factor Xa together” or “oligopeptide recognizable by coagulation factors XIa and Xa together, or oligopeptide recognizable by thrombin and coagulation factor Xa together” are used to indicate the tripeptide EPR (GluProArg) or a peptide fragment containing EPR, or pentapeptide GVYAR (GlyValTyrAlaArg) or the peptide fragment containing GVYAR.
- the anticoagulation substance comprising an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together is preferably linked with EPR or GVYAR at the amino-terminal of hirudin.
- the anticoagulation substance comprising the oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or the oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together may be expressed in appropriate host systems, preferably expressed in E. coli or yeast.
- FIG. 1 shows nucleotide sequences of EH and GH.
- FIG. 2 shows amino acid sequences of EH and GH.
- EH EPR-HV2
- GH GVYAR-HV2
- a restriction site XhoI and a base sequence encoding the EPR sequence co-recognizable by coagulation factors XIa and Xa or the GVYAR sequence co-recognizable by thrombin and coagulation factor Xa were introduced at upstream of hirudin (HV2) gene, and a restriction site EcoRI was introduced at downstream of the gene.
- HV2 hirudin
- EcoRI was introduced at downstream of the gene.
- This gene was incorporated into pPIC9 plasmid that was digested by the same enzymes, thus recombinant plasmids pPIC-EH and pPIC9-GH were obtained.
- pPIC-EH and pPIC9-GH were digested with BamHI and SalI, and ligated to plasmid pPIC9K that was digested by the same enzymes, then pPIC9K-EH and pPIC9K-GH were obtained.
- the two recombinant plasmids were introduced into the yeast genome by electrotransformation and subjected to induction of expression by methanol. The expressed products were isolated and purified to get the proteins of interest of EH and GH.
- HV2 hirudin
- NS normals saline. * P ⁇ 0.05, **P ⁇ 0.01 compared with NS group; ⁇ P ⁇ 0.01, HV2 group compared with each of the other groups.
- GH and EH had a much less effect on bleeding index than that of FH and TH, and particularly GH had a significantly shorter bleeding time than that of FH and TH group, indicating that GH and EH are significantly better than FH or TH in decreasing hemorrhagic side-effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This invention belongs to the area of biotechnology, and relates to structure and preparation of a kind of anticoagulant substances with low hemorrhage and their application in prevention and treatment of thrombosis and thrombosis-related diseases. Particularly, this invention is related to a new substance obtained by linking an anticoagulant substance and an amino acid sequence being recognizable and cleavable by several blood coagulation factors, including thrombin, blood coagulation factor Xa (FXa) and XIa (FXIa) etc., and the preparation and pharmaceutical use of the same.
- Cardio-cerebrovascular diseases are number one killer threatening human health and life, and thrombosis is an important cause of many cardio-cerebrovascular diseases. Therefore, anticoagulants are important medicines used to prevent thrombosis. At present, heparin is an anticoagulant extensively used in clinical treatment. But one of its important shortcomings is to initiate thrombocytopenia. The newly developed Low-Molecular-Weight (LMW) heparin might decrease above risks, but can not thoroughly overcome its shortcomings.
- People have focused more and more on above-mentioned shortcomings of prior anticoagulants. As an ideal anticoagulant, it should have the clear and definite anticoagulant effect, and should not cause the hemorrhagic side-effect in the case of systemic administration, so as to increase the clinical safety.
- For this purpose, the key point of guiding principles for the present invention is that the anticoagulant function should be conditionally and specifically activated. That is, this kind of material normally has no anticoagulant activity, and only when the coagulation system is activated, and thrombus is possible to form or the thrombus formed, then this kind of anticoagulant locally display their anticoagulant activities. The local anticoagulant activity around the developing or developed thrombus forms a microenvironment to prevent thrombosis or the continued growing of the thrombus, even to dissolve the formed minute thrombus so as to attain the prophylactic/therapeutic purposes. Therefore, this invention would overcome the risk of systemic hemorrhage which often happens with administration of anticoagulant agents, such as heparin, hirudin etc.
- For example, hirudin is a single chain polypeptide consisting of 65-66 amino acid residues, whose amino terminus can bind with the catalytic active site of thrombin, and possesses anticoagulant activity, and the binding of its C-terminus with the recognition site of thrombin substrate shows a very strong specific affinity to thrombin. This study designed a measure to block the amino-terminus of hirudin so as to diminish hirudin's anticoagulant activity temporarily. When the in vivo coagulation system is activated and thrombus formed, the special biochemical changes incited by thrombosis make the amino terminal-blocked hirudin recovered to the original form of hirudin displaying the specific anticoagulation effect at the location of potential or occurred thrombosis, thereby the systemic hemorrhagic side effect could be decreased. Therefore, this is a new type of safe and effective anticoagulant agent.
- Under guidance of the above-mentioned inventive idea, hirudin was modified in this study. Hirudin first was linked by its amino-terminal with an oligopeptide recognizable and cleavable by thrombin, which is named as TH, or with an oligopeptide recognizable and cleavable by blood coagulation factor Xa, which is named as FH, so that once the coagulation system was activated, the anticoagulant activity of hirudin derivatives could be released and play the anticoagulant and antithrombotic roles, while the hemorrhagic side-effect would be also decreased. The results indicated that the modified hirudin was functional, but the effectiveness was not still high enough. Then, we developed our idea and considered that the hirudin might be modified by linking with an oligopeptide which can be recognized and cleaved by several blood coagulation factors or other factors. We hoped that the effectiveness could be enhanced by the above-mentioned modification to the extent of applicability to clinical practice. At present, however, on the basis of the related references, we can not infer if these oligopeptides can be recognized and cleaved by the corresponding blood coagulation factors in high efficiency. Two related proteins were prepared in our laboratory as follows: (1) hirudin was linked at its amino-terminal with the oligopeptide being recognizable and cleavable by both thrombin and coagulation factor Xa, this hirudin derivative being named as GH; (2) hirudin was linked at its amino-terminal with the oligopeptide being recognizable and cleavable by both coagulation factors XIa and Xa, this hirudin derivative being named as EH.
- The research results indicated that these two derivatives of hirudin normally had no anticoagulation activity whether in vitro or in vivo, and could effectively release anticoagulation activity of hirudin locally under coacting of the above mentioned blood coagulation factors once coagulation system being activated, blood coagulation factors and play both roles of anticoagulation and antithrombosis. Certainly, There was no anticoagulation activity in the site of the body where thrombosis was absent, and thus their systemic hemorrhagic side-effect was also notably decreased. Therefore, unlike anticoagulant, such as hirudin and heparin, they are a kind of safe, effective anticoagulant and antithrombotic agents. As a result, this kind of anticoagulant agents with the characteristics of low hemorrhage is of importance to the application in prevention and/or treatment of thrombosis.
- This invention is aimed at providing a kind of substance which has no anticoagulant activity itself and can release its anticoagulation activity around the site of thrombosis when thrombosis tends to occur or is occurring for prevention and/or treatment of thrombosis.
- It is discovered in this invention that the anticoagulation activity of the anticoagulation substance could be blocked by linking the anticoagulation substance with a sequence recognizable by both coagulation factor XIa and Xa, or a sequence recognizable by both thrombin and coagulation factor Xa, and the new anticoagulation substance is cleavable at certain conditions. The derivatized anticoagulation substances possess the following characteristics: after blocked by a sequence recognizable by the above-mentioned two blood coagulation factors, the anticoagulation substance, such as hirudin, has no anticoagulation activity both in vitro and in non-thrombotic site of blood system, thus avoiding or decreasing the side-effects of systemic hemorrhage caused by anticoagulation substances, such as hirudin; the derivatized anticoagulation substances can locally release free anticoagulant substances under the action of blood coagulation factors specifically present in the site of thrombosis only when the thrombosis occurs, thus displays a prophylactic and/or therapeutic effects against thrombosis, and therefore significantly decreases the side-effect of systemic hemorrhage. Furthermore, the new anticoagulation substance, such as the amino-terminus of hirudin, blocked with a two coagulation factors-recognized sequence, can be cleaved by two coagulation factors together, the effectiveness of which is greatly superior to that of the block of anticoagulation substance by a one coagulation factor-recognized sequence. The discovery of this invention based on the above-mentioned characteristics has been completed at present.
- Therefore, on the one hand, this invention is related to an anticoagulation substance which comprises an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together.
- This invention, on the other hand, is related to a method for preparation of an anticoagulation substance comprising an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together, which comprises ligating a gene encoding anticoagulation protein with an base sequence corresponding to the sequence recognizable and cleavable by coagulation factors XIa and Xa together, or to the sequence recognizable and cleavable by thrombin and coagulation factor Xa together, then inserting the recombinant gene into a suitable expression vector, such as pBV220, pPIC9, and pPIC9K etc, and expressing the recombinant vector containing the gene of interest in appropriate host cells, such as Escherichia coli, yeast or animal cell systems, so as to obtain the new anticoagulation substance.
- In further aspect, this invention is related to a pharmaceutical composition comprising the above-mentioned new anticoagulation substance and a pharmaceutically acceptable carrier or excipient.
- According to the present invention, the term “anticoagulant substance” or “anticoagulation substance” indicates a substance against blood coagulation, such as hirudin, antithrombin III, snake venom etc. or their mutants; or the other substances with anticoagulation activity, preferably hirudin or its mutants.
- According to the present invention, the terms “linked peptide recognizable by coagulation factors XIa and Xa together or linked peptide recognizable by thrombin and coagulation factor Xa together” or “oligopeptide recognizable by coagulation factors XIa and Xa together, or oligopeptide recognizable by thrombin and coagulation factor Xa together” are used to indicate the tripeptide EPR (GluProArg) or a peptide fragment containing EPR, or pentapeptide GVYAR (GlyValTyrAlaArg) or the peptide fragment containing GVYAR.
- According to the present invention, the anticoagulation substance comprising an oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or an oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together is preferably linked with EPR or GVYAR at the amino-terminal of hirudin.
- According to the present invention, the anticoagulation substance comprising the oligopeptide recognizable and cleavable by coagulation factors XIa and Xa together, or the oligopeptide recognizable and cleavable by thrombin and coagulation factor Xa together may be expressed in appropriate host systems, preferably expressed in E. coli or yeast.
-
FIG. 1 shows nucleotide sequences of EH and GH. -
FIG. 2 shows amino acid sequences of EH and GH. - The following examples further illustrate this invention, but do not mean any limitation on this invention.
- I. Preparation of EH and GH protein
- Through PCR, a restriction site XhoI and a base sequence encoding the EPR sequence co-recognizable by coagulation factors XIa and Xa or the GVYAR sequence co-recognizable by thrombin and coagulation factor Xa were introduced at upstream of hirudin (HV2) gene, and a restriction site EcoRI was introduced at downstream of the gene. This gene was incorporated into pPIC9 plasmid that was digested by the same enzymes, thus recombinant plasmids pPIC-EH and pPIC9-GH were obtained. pPIC-EH and pPIC9-GH were digested with BamHI and SalI, and ligated to plasmid pPIC9K that was digested by the same enzymes, then pPIC9K-EH and pPIC9K-GH were obtained. The two recombinant plasmids were introduced into the yeast genome by electrotransformation and subjected to induction of expression by methanol. The expressed products were isolated and purified to get the proteins of interest of EH and GH.
- II. Biological Activity of EH and GH
- 1. Analysis of Activities In Vitro
- EH, GH, FH and TH were cleaved respectively by thrombin, FXa and FXIa, then the activities of anticoagulation were assayed by fibrin-clot method. The results were listed in Table 1.
TABLE 1 Analyses of anticoagulation activity of EH, GH, FH and TH before and after cleavage by thrombin, FXa and FXIa GH FH TH EH group 0 h 3 h 6 h 0 h 3 h 6 h 0 h 3 h 6 h 0 h 3 h 6 h thrombin 0 2 8 0 2 8 0 0 0 0 0 0 FXa 0 64 128 0 64 128 0 32 64 0 64 128 FXIa 0 0 0 0 0 0 0 0 64 0 256 512 - It was shown in Table 1 that GH can be recognizable and cleavable by two blood coagulation factors of FXIa and FXa respectively, EH can be recognizable and cleavable by two blood coagulation factors of thrombin and FXa respectively, while FH only by FXa and TH only by thrombin.
- 2. Analysis of Antithrombosis and Hemorrhagic Side-Effects of GH and EH
- (1) Analyses of GH, EH, FH and TH antithrombotic and hemorrhagic side-effects in rat carotid artery thrombosis model, and the results were listed in table 2 and 3.
TABLE 2 Influence of GH, EH, FH and TH on time needed for thrombogenesis in rat cartoid artery HV2 EH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg Time needed for 779.30 ± 193.47 1117.00 ± 243.95## 964.10 ± 179.68# 1083.90 ± 227.10## thrombogenesis (s) HV2 GH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg Time needed for 779.30 ± 193.47 1117.00 ± 243.95## 918.10 ± 204.16 1006.7 ± 227.37# thrombogenesis (s) HV2 FH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg Time needed for 779.30 ± 193.47 1117.00 ± 243.95## 988.10 ± 231.16 1096.0 ± 255.9# thrombogenesis (s) HV2 TGH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg Time needed for 779.30 ± 193.47 1117.00 ± 243.95## 881.50 ± 145.18 927.80 ± 152.84# thrombogenesis (s)
Each group was consisted of 10 animals and the results were shown asX ± SD; HV2: hirudin; NS: normal saline. #p < 0.05, ##p < 0.01, compared to NS group
-
TABLE 3 Influence of EH, GH, FH and TH on plasma TT levels in rat carotid artery thrombosis model HV2 EH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg % of TT changes 100 ± 0 1005.62 ± 361.28** 108.41 ± 12.95 121.81 ± 13.68** HV2 GH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg % of TT changes 100 ± 0 1005.62 ± 361.28** 104.35 ± 17.21 114.94 ± 19.82** HV2 FH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg % of TT changes 100 ± 0 1005.62 ± 361.28** 119.31 ± 16.32 149.66 ± 50.84* HV2 TH group NS 2 mg/ kg 2 mg/ kg 4 mg/kg % of TT changes 100 ± 0 1005.62 ± 361.28** 117.57 ± 14.82 141.03 ± 54.31*
Each group was consisted of 10 animals and the result of NS group was shown as 100%, and the results of other groups were expressed as the percentage changes of each group compared with NS group. The results were expressed asX ± SD. HV2: hirudin, NS: normals saline. * P < 0.05, **P < 0.01 compared with NS group; □P < 0.01, HV2 group compared with each of the other groups.
- (2) The hemorrhagic side-effects of GH, EH, TH and FH in hemorrhagic model of tail-cut mouse were analyzed, and the results were listed in Table 4.
TABLE 4 Influence of EH, GH, FH and TH on bleeding time if tail-cut mouse HV2 EH group NS 1.5 mg/kg 1.5 mg/kg 6 mg/kg Bleeding times (s) 156.14 ± 125.08 1532.5 ± 420.74 203.89 ± 97.41 338.77 ± 169.08* HV2 GH group NS 1.5 mg/kg 1.5 mg/kg 6 mg/kg Bleeding time (s) 156.14 ± 125.08 1532.5 ± 420.74 165.46 ± 142.42 304 ± 178.99*# HV2 FH group NS 1.5 mg/kg 1.5 mg/kg 6.0 mg/kg Bleeding time (s) 156.14 ± 125.08 1532.5 ± 420.74 264.08 ± 209.74 569.14 ± 430.1* HV2 TH group NS 1.5 mg/kg 1.5 mg/kg 6 mg/kg Bleeding time (s) 156.14 ± 125.08 1532.5 ± 420.74 241.42 ± 194.49 397.31 ± 286.12*
Each group was consisted of 15 animals and the result was expressed asX ± SD. *P < 0.05, compared wwith NS group; □ P < 0.01, HV2 group compared with each of the other groups; # P < 0.05, GH group compared with FH and TH group.
- It was observed from table 2 that the time needed for thrombogenesis was prolonged in a dose-dependent manner by EH, GH, FH and TH in rat carotid artery thrombosis model, which indicated that each of the four derivatives of hirudin had the ability to function against arterial thrombosis, with efficacies substantially similar to each other. However, the hemorrhagic side-effects were quite different from each other. From table 3 and 4, it was shown that the influence of GH, EH, FH and TH on hemorrhagic indexes is less than that of HV2, indicating a higher safety of them than that of HV2. However, GH and EH had a much less effect on bleeding index than that of FH and TH, and particularly GH had a significantly shorter bleeding time than that of FH and TH group, indicating that GH and EH are significantly better than FH or TH in decreasing hemorrhagic side-effect.
Claims (9)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610165756 | 2006-12-15 | ||
CN200610165756 | 2006-12-15 | ||
CN200610165756.7 | 2006-12-15 | ||
WOPCT/CN2007/003526 | 2007-12-11 | ||
PCT/CN2007/003526 WO2008071081A1 (en) | 2006-12-15 | 2007-12-11 | Preparation of low bleeding anticoagulant fusion protein and its use |
Publications (3)
Publication Number | Publication Date |
---|---|
US20100113345A1 US20100113345A1 (en) | 2010-05-06 |
US20100234291A2 true US20100234291A2 (en) | 2010-09-16 |
US8101379B2 US8101379B2 (en) | 2012-01-24 |
Family
ID=39511252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/519,309 Active US8101379B2 (en) | 2006-12-15 | 2007-12-11 | Preparation of low bleeding anticoagulant fusion protein and its use |
Country Status (6)
Country | Link |
---|---|
US (1) | US8101379B2 (en) |
EP (1) | EP2103630B1 (en) |
JP (1) | JP5345069B2 (en) |
CN (1) | CN101668778B (en) |
AT (1) | ATE533789T1 (en) |
WO (1) | WO2008071081A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045503A1 (en) | 2004-10-19 | 2006-05-04 | Lonza Ag | Method for solid phase peptide synthesis |
CN102180973B (en) * | 2011-03-18 | 2012-08-29 | 重庆大学 | Target multifunctional anti-embolism fusion protein as well as preparation method and application thereof |
CN109206522B (en) * | 2017-07-07 | 2021-11-09 | 北京三有利和泽生物科技有限公司 | Long-acting anticoagulant fusion protein and application thereof |
CN115572329B (en) * | 2021-06-21 | 2024-02-06 | 王大勇 | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof |
CN113956339B (en) * | 2021-10-28 | 2023-02-24 | 中国药科大学 | Whitmania pigra anticoagulant factor XIa polypeptide and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910481A (en) * | 1995-11-13 | 1999-06-08 | Immuno Ag | Hybrid proteins with modified activity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759542A (en) * | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
ATE205506T1 (en) * | 1995-06-12 | 2001-09-15 | Sanquin Bloedvoorziening | FACTOR IX BINDING PEPTIDES DERIVED FROM FACTOR VII AND THEIR USE AS BLOOD CLOTTING INHIBITORS |
CN1480466A (en) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | Interfusion protein possessing dual functions of thrombolysis and anticoagulation as well as its application |
CN1896108B (en) * | 2005-06-01 | 2012-01-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Preparation of specific anticoagulation matter and its use |
-
2007
- 2007-12-11 EP EP07845883A patent/EP2103630B1/en active Active
- 2007-12-11 CN CN2007800463406A patent/CN101668778B/en active Active
- 2007-12-11 JP JP2009540580A patent/JP5345069B2/en active Active
- 2007-12-11 WO PCT/CN2007/003526 patent/WO2008071081A1/en active Application Filing
- 2007-12-11 AT AT07845883T patent/ATE533789T1/en active
- 2007-12-11 US US12/519,309 patent/US8101379B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910481A (en) * | 1995-11-13 | 1999-06-08 | Immuno Ag | Hybrid proteins with modified activity |
US6156888A (en) * | 1995-11-13 | 2000-12-05 | Baxter Aktiengesellschaft | Hybrid proteins with modified activity |
Also Published As
Publication number | Publication date |
---|---|
US8101379B2 (en) | 2012-01-24 |
CN101668778B (en) | 2012-10-03 |
US20100113345A1 (en) | 2010-05-06 |
WO2008071081A1 (en) | 2008-06-19 |
EP2103630B1 (en) | 2011-11-16 |
ATE533789T1 (en) | 2011-12-15 |
JP5345069B2 (en) | 2013-11-20 |
EP2103630A4 (en) | 2010-07-28 |
WO2008071081A8 (en) | 2009-08-13 |
JP2010512349A (en) | 2010-04-22 |
EP2103630A1 (en) | 2009-09-23 |
CN101668778A (en) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2771208T3 (en) | Factor VIII compositions and methods of preparation and use thereof | |
JP5813641B2 (en) | Coagulation factor IX composition and methods of making and using the same | |
CN105008397B (en) | Gla domains as therapeutic agents | |
CN110330563B (en) | Modified serine protease inhibitors for the treatment of hemorrhagic diseases | |
WO2015066550A1 (en) | Therapeutic nuclease-albumin fusions and methods | |
US8101379B2 (en) | Preparation of low bleeding anticoagulant fusion protein and its use | |
CN108289851A (en) | Long-acting coagulation factors and its production method | |
US20060029590A1 (en) | Administration of neutral endopeptidase to treat inflammatory bowel disease | |
CN1301268C (en) | Thrombus-resolving and anticoagulation double function fusion protein and use thereof | |
CN101190945A (en) | Preparation for specificity anticoagulant substance and application thereof | |
JPH04505554A (en) | Soluble thrombomodulin analogs | |
TW200529870A (en) | Therapeutic use of factor XI | |
US20040185038A1 (en) | Methods for reducing immunogenicity of polypeptides | |
CN1896108B (en) | Preparation of specific anticoagulation matter and its use | |
CN113968901A (en) | Use of protein sequences that bind to substrates for the preparation of products inhibiting fibrin assembly | |
CN107083366A (en) | Express adoptive immunity cell of hirudin and its production and use | |
WO2008046256A1 (en) | Haemocoagulase | |
CN102443065A (en) | Preparation for specificity anticoagulant substance and application thereof | |
EP2507266A2 (en) | TREATMENT OF IgE-MEDIATED DISEASE | |
Rushe | Engineered soluble protein C pathway receptors as novel pro-haemostatic agents | |
EP4021570A1 (en) | Treatment of non-alcoholic steatohepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, ZUZE;YU, AIPING;ZHANG, CHUANLING;AND OTHERS;REEL/FRAME:023675/0936 Effective date: 20090803 Owner name: BEIJING SANLY SCI-TECH DEVELOP INC. LTD.,CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, ZUZE;YU, AIPING;ZHANG, CHUANLING;AND OTHERS;REEL/FRAME:023675/0936 Effective date: 20090803 Owner name: BEIJING SANLY SCI-TECH DEVELOP INC. LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, ZUZE;YU, AIPING;ZHANG, CHUANLING;AND OTHERS;REEL/FRAME:023675/0936 Effective date: 20090803 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |